Investigational drug · Phase 2
BLU-808
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, Allergic Rhinoconjunctivitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "BLU-808"
First trial start
2025
Apr 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BLU-808", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Inducible Urticaria
- Chronic Spontaneous Urticaria
- Allergic Rhinoconjunctivitis
Approved drugs for the same conditions: Chronic hives (urticaria) · Immunology and inflammation · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "BLU-808" as an intervention, largest first.
- Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)Pivotal-lookingCompleted
Blueprint Medicines CorporationIndustry
NCT06931405 · 110 participants · Start May 28, 2025 · Primary completion Oct 15, 2026
Drug: BLU-808; Placebo · For: Chronic Inducible Urticaria; Chronic Spontaneous Urticaria
Sites: Birmingham, Alabama; Little Rock, Arkansas; La Jolla, California · 47 sites in all
Blueprint Medicines CorporationIndustry
NCT06948032 · 95 participants · Start Aug 7, 2024 · Primary completion Jan 21, 2025
Drug: BLU-808; Placebo and 1 more · For: Healthy Participants
Sites: Lincoln, Nebraska
Blueprint Medicines CorporationIndustry
NCT06922448 · 21 participants · Start Apr 14, 2025 · Primary completion Sep 8, 2025
Drug: BLU-808; Placebo · For: Allergic Rhinoconjunctivitis
Sites: Ottawa, Canada
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Inducible Urticaria
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- EVO756Phase 24 trials
Evommune, Inc. · Migraine, Chronic Inducible Urticaria, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.